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Highlights
 We systematically reviewed the socioeconomic cost literature for 10 rare 
diseases.
 Direct and indirect costs incurred by patients, carers and society were searched.
 77 studies were included with an unequal distribution of studies over disease 
types.
 Level of existing evidence is highest for diseases with available drug treatments.
 Indirect costs are in most cases of similar or higher magnitude than direct costs.
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Abstract
Cost-of-illness studies, the systematic quantification of the economic burden of diseases 
on the individual and on society, help illustrate direct budgetary consequences of 
diseases in the health system and indirect costs associated with patient or carer 
productivity losses. In the context of the BURQOL-RD project (“Social Economic Burden 
and Health-Related Quality of Life in patients with rare diseases in Europe”) we studied
the evidence on direct and indirect costs for 10 rare diseases (Cystic Fibrosis [CF], 
Duchenne Muscular Dystrophy [DMD], Fragile X syndrome [FXS], Haemophilia, Juvenile 
Idiopathic Arthritis [JIA], Mucopolysaccharidosis [MPS], Scleroderma, Prader-Willi 
Syndrome [PWS], Histiocytosis and Epidermolysis Bullosa [EB]). A systematic literature 
review of cost of illness studies was conducted using a keyword strategy in combination 
with the names of the 10 rare diseases.  Available disease prevalence in Europe was
found to range between 1-2 per 100,000 population (PWS, a sub-type of Histiocytosis,
and EB) up to 42 per 100,000 population (Scleroderma). Overall, cost evidence on rare 
diseases appears to be very scarce (a total of 77 studies were identified across all 
diseases), with CF (n=29) and Haemophilia (n=22) being relatively well studied, 
compared to the other conditions, where very limited cost of illness information was 
available. In terms of data availability, total lifetime cost figures were found only across 
four diseases, and total annual costs (including indirect costs) across five diseases. 
Overall, data availability was found to correlate with the existence of a pharmaceutical 
treatment and indirect costs tended to account for a significant proportion of total costs. 
Although methodological variations prevent any detailed comparison between 
conditions, most of the rare diseases examined are associated with significant economic 
burden, both direct and indirect.
Keywords
Cost of illness; Rare diseases; Socioeconomic impact; Systematic review; Orphan drugs; 
BURQoL-RD
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1. Introduction
Most rare diseases are associated with high unmet need due to the lack of available and
effective treatments and the relative lack of research to discover and develop such 
treatments. In the European Union (EU), a rare disease is defined as one affecting less 
than 1 in 2,000 people, and it is estimated that over 6,000 different, life-threatening or
chronic, rare diseases exist today (1). Although rare diseases are by definition 
associated with low prevalence, considering that 6% - 8% of the population are affected 
by a rare disease, the total number of patients in the EU is estimated to be between 27 
and 36 million (2). With the majority of rare disease patients suffering from less 
frequent conditions with a prevalence of 1 in 100,000 population, and with many rare 
diseases being of genetic origin, there is a strong public health interest relating to their 
cost and broader socioeconomic impact in order to develop sustainable health policy 
options.  
Cost-of-illness (COI) studies measure the socio-economic burden of a disease and can be 
used as a public policy tool to assist in prioritization and justification of healthcare and 
prevention policies (3). COI studies can indicate which interventions are more valuable 
by comparing averted economic burden, and consequently lead to shifts in distribution 
of public and private investments. Different stakeholders can utilise COI studies 
differently. Governments can estimate the financial impact of a disease on public 
budgets for resource allocation purposes, whereas pharmaceutical corporations can
identify diseases with high management costs to direct research and development 
(R&D) investments towards accordingly.
In addition, COI studies provide information for other types of economic evaluations, 
including a framework for cost estimation in cost-utility and cost-effectiveness analyses, 
frequently used by policy makers (3, 4). They are increasingly cited in clinical and 
epidemiological research to emphasize the importance of studying a particular disease
and the scale of a problem, conveying the aggregate burden of illness on society by 
estimating the maximum amount that could potentially be saved if a disease were to be 
eradicated (5, 6).  
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While COI studies can identify and measure all costs of a particular disease, they do not 
address issues of inefficiency or waste, or weigh up costs and benefits of interventions
(6). Caution is also advisable when interpreting COI estimates as potential savings if a 
disease were systematically targeted, as not all conditions can be fully eradicated, and 
some proportion of economic burden will remain despite effective interventions (6).
For optimal resource allocation, COI studies should be used in combination with full 
economic evaluations such as cost-benefit or cost-utility analyses which assess both 
costs and outcomes (7).
COI studies employ a wide range of different designs and methodologies, often limiting 
comparability and usefulness of results (8). Variations include data sources, 
perspectives (healthcare, societal, etc.), cost types, costing approach and discount
rate(9).  While standardisation of methodology through implementation of guidelines is 
becoming increasingly important, some flexibility may be required for diseases with 
special characteristics to be adequately described (3, 9).
Numerous COI studies have been conducted over the past three decades across a range 
of diseases, however few have addressed rare diseases. In this context, the aim of the 
BURQOL-RD project (“Social Economic Burden and Health-Related Quality of Life in 
patients with Rare Diseases in Europe”) was to provide new tools and knowledge for 10
rare diseases (RDs), including socio- conomic burden and health related quality of life 
for patients and their caregivers (10).
The objective of this study is to systematically review the relevant literature on the 
socioeconomic burden of RDs and identify all costs, both direct and indirect, related to 
ten specifically identified RDs from the perspective of patients, families and society.
2. Data and methods
The BURQOL-RD project participants adopted a Delphi consensus approach in 
combination with a Carroll diagram for the selection of the 10 RDs to be studied (10).
An expert panel involved 23 individuals as representatives of each associated and 
collaborating project partner. Initially, the selection criteria for the potential RDs were 
defined and were summarised under the acronym BOSCARE: these included a Broad 
spectrum of RDs should be suitably represented, including some ultra-rare and less 
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frequently researched RDs; the availability of strong and well-Organised patient 
associations for specific RDs in most participating Member States ensuring adequate 
recruitment and participation rates; taking advantage of previous Studies carried out by 
Eurordis and other national/regional associations, to consider at least some of the RDs 
included in such studies for which a minimum threshold of participation was obtained; 
select RDs where in the absence of effective therapies a professional network can offer 
integrated advice, CAre and support for the affected families; and availability of rare 
disease REgistries, European research networks financed by the European Union DG-
Sanco or networks of reference centres. Subsequently, a two-round Delphi panel 
process yielded a prioritised list of diseases. A questionnaire was administered to all 
experts via e-mail. In the first round, the questionnaire offered the BOSCARE criteria 
and an initial set of candidate RDs; each expert was asked to select 10 diseases 
according to the BOSCARE criteria and rank them by importance. In the second round, 
members were provided with their own rankings as well as with the overall results of 
the first round for the panel, and a revision of their ranking was requested. Based on 
this approach a shortlist of 36 RDs emerged following the end of the first round, and a 
total of 33 RDs were shortlisted following the end of the second round. The following 
step involved a joint discussion among the expert panel, where six potential 
determinants were identified, notably (a) prevalence of ≥1/10,000 or <1/10,000; (b) 
age at onset and whether this was during adulthood or childhood; (c) the extent to 
which the disease was genetic or had other origin; (d) whether or not the disease 
resulted in physical impairment and/or mental impairment; (e) whether or not there 
exist valid diagnostic tests; and (f) whether or not there is availability of effective 
therapies to modify the disease course. Experts provided a ranking for the conditions 
based on these determinants. Finally, in the group of shortlisted conditions from the 
above step, a Carroll trilateral diagram was applied taking into account three 
determinants, namely (a) prevalence, (b) availability of effective treatments and (c) 
need for carer.
The final set of 10 rare conditions included Cystic Fibrosis (CF), Duchenne Muscular 
Dystrophy (DMD), Fragile X syndrome (FXS), Haemophilia, Juvenile Idiopathic Arthritis
(JIA), Mucopolysaccharidosis (MPS), Scleroderma, Prader-Willi Syndrome (PWS), 
Histiocytosis and Epidermolysis Bullosa (EB). In selecting the final list of RDs for this 
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project, efforts were made to include both rare and ultra-rare diseases review as well as 
diseases that did have some pharmacological treatment versus diseases that did not.
Based on the agreed-upon disease sample, a systematic literature review of COI was 
undertaken using the following five keywords in conjunction with the names of the 10 
RDs identified above: cost of illness; spending; financial expenditure; financial burden; 
costs. 
PubMed and the Web of Science (WoS) databases were searched in March 2011. All 
studies published prior to this date were eligible for inclusion. The resulting studies 
were filtered to identify their suitability for inclusion based on whether they provided 
evidence of costs, both direct (either medical or non-medical related)_and indirect (i.e. 
productivity loss). 
All costs were converted to 2010 Euros (€). Given the limitations of the European 
Central Bank (ECB) Statistical Data Warehouse (does not provide currency conversion 
rates before 1999, which is later than some of the cost figures identified and,
additionally, it does not cover European currencies prior to their accession to the Euro),
exchange rates were retrieved using the PACIFIC Exchange Rate Service from the 
University of British Columbia (monthly averages, price notation)(11). Prices were 
adjusted to 2010 levels before conversion using Average Consumer Price Inflation 
figures (12). 
<Figure 1 about here>
3. Results
3.1 Disease characteristics and prevalence in Europe
By reviewing the available evidence on disease characteristics and their 
prevalence/rarity, a better understanding of the burden of the different diseases can be 
gained. In turn, the limited availability of COI evidence suggests the need for further 
research on the selected RDs. Prevalence for each disease is shown on Table 1. 
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CF is the most frequent pediatric autosomal recessive disease in Caucasian populations
(13-15), occurring in 1 in 2,500 to 3,600 births, with a European Union (EU) prevalence 
of 12.6:100,000 population (16).  CF causes abnormalities in chloride ion transportation 
resulting in increased viscosity of mucus secretions within numerous organ systems.  
This impacts primarily the lungs and respiratory function, the pancreas, fat digestion,
and, over the long-term, liver function.  Respiratory failure is the primary cause of 
morbidity and mortality in CF patients (17).  The disease was originally considered 
pediatric as most did not survive past adolescence, however, improvements in daily 
routines, medical management and pharmacological support have allowed increasing 
numbers of patients to survive until middle adulthood.  
DMD is a recessive X-linked type of muscular dystrophy, affecting boys only.  The 
condition appears in early childhood, resulting in muscle degeneration affecting 
mobility, spinal development and breathing.  Life expectancy ranges from teenage to 
early adulthood.  Treatment is largely supportive via physical therapy and medical 
appliances and home modifications, although some clinical trials are being performed 
on beta-agonists.  The condition affects approximately 1 in 4,000 male infants(18), with 
an EU prevalence of 5 per 100,000 population (16).
Fragile X syndrome (FXS), otherwise known as Martin-Bell syndrome or Escalante’s 
syndrome, is an X-linked dominant genetic disorder resulting primarily in autism and 
other mental disability (19).  The prevalence of the disease is 1:3,600 males and 
1:4,000-6,000 females(20) and the EU prevalence is estimated to be 20 per 100,000
population (16).
Haemophilia is a recessive X-linked disorder resulting in lowered clotting factors, which 
prevent coagulation and clotting from occurring.  This causes difficulties in maintaining
a blood clot to start the healing process and causes bleeding to last for longer. There are 
three types: haemophilia A, B and C (autosomal) with poorly functioning clotting Factor 
VIII (80% of patients), IX (20% of patients) and XI respectively.  Treatment involves 
regular infusions of Factors VIII, IX or XI from human or recombinant blood products.  
The incidence of haemophilia A varies by country at 1:5,000-10,000 males while 
haemophilia B is 1:20,000-34,000 males (21), with an overall haemophilia prevalence in 
the EU at 7.7 per 100,000 population (16). Haemophilia has been divided into three 
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levels of severity – mild (5-40% clotting factor), moderate (1-5%) and severe (<1%).  
Treatment with clotting factor VIII or IX may result in the production of antibodies, 
known as inhibitors, causing standard treatment to become ineffective and bleeding 
more difficult to control.  More advanced drugs have been developed to treat patients 
with inhibitors.  Further, as treatment involves regular use of blood products, patient 
are exposed to the risks of Hepatitis C (HCV)/Human Immunodeficiency Virus (HIV) 
infection, particularly up until the mid-1990s when the virus testing window was large
and before the mid-1980s when blood safety was poorer compared with current 
standards.  As a result, a significant number of haemophilia patients are infected with 
HCV/HIV, making their treatment and management more difficult.
JIA is the most common form of childhood arthritis, primarily affecting knees, ankles, 
wrists, hand and feet.  Chronic pain is commonplace, and over time joints become 
damaged and contracted resulting in growth retardation (also an effect of long term 
steroid use).  There are three classifications: oligoarticular (≤4 joints in first 6 months; 
50% of children), polyarticular (≥5 joints in first 6 months; 40% of children) and 
systemic (joint and organ involvement; 10% of children).  Treatment involves physical 
therapy, medication (anti-inflammatory drugs, corticosteroid injections, TNF alpha 
blockers), surgery and occupational therapy.  It has an estimated prevalence of 8-150 
children in every 100,000 (22), and an overall prevalence estimate in the EU at 5.0 per 
100,000 population (16).
MPS is a group of metabolic disorders where the body does not produce sufficient 
enzymes needed for glycosaminoglycans breakdown (long chains of sugar 
carbohydrates in the cells aiding bone, cartilage, tendons, corneas, skin and connective 
tissue growth) and are part of the lysosomal storage disease family. There are a number 
of MPS types, from MPS I to MPS IX each with varying incidence, sub-types and deficient 
enzymes (Type I, with prevalence of 1:100,000 to 1:500,000 population; Type II,
1:100,000 to 1:170,000 males; Type III, 1:70,000; Type IV, 1:200,000 to 1:300,000; Type 
VI, 1:250,000 to 1:600,000)(23-27). In the EU, the overall prevalence for all types of 
MPS is estimated to be 3:100,000 population (16). MPS Type I, also known as Hunter’s 
Disease, is commonly differentiated into severe and attenuated types resulting in 
mental retardation and, often, poor cardiac and liver development.  Symptoms are 
usually apparent early in life, at times as young as one year old (23). MPS Type VI, also
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known as Maroteaux–Lamy syndrome, primarily obstructs bone development resulting 
in short stature, skeletal and joint deformities. While patients with the rapidly 
progressive phenotype tend to die before adulthood, those with a slowly progressive 
phenotype may live into their 40s or 50s.  Recently, a new treatment, enzyme 
replacement therapy (ERT) (recombinant human ASB enzyme, rhASB) has been made 
available, potentially improving patient quality of life (28). 
Scleroderma is a connective tissue disorder resulting in changes in the skin, muscles, 
blood vessels and internal organs due to a buildup of collagen in these organs.  The 
cause is unknown, however, it does run in some families and some risk factors have 
been identified, such as industrial exposure to silica dust and polyvinyl chloride.  More 
common in women than men, scleroderma tends to affect individuals between 30 and 
50 years of age (29). The prevalence of scleroderma is estimated to be around 
74:100,000 among women and 13:100,000 among men (30), with an overall EU 
prevalence being 42:100,000 population (16).
Prader-Willi syndrome (PWS) is a congenital genetic disease where seven genes on 
chromosome 15 are deleted or not expressed.  This results in obesity due to 
hyperphagia, poor muscle tone, sex glands produce little or no hormones, as well as 
often below average intelligence and learning difficulties (31).  Estimations of the 
incidence of PWS vary depending on the study and country studied, but it is in the 
region of 1:22,000 births (32), with an EU prevalence of 1.6:100,000 population (16). 
Few therapies exist for PWS.  Growth hormone therapy (GHT) has been authorized by 
the FDA for the treatment of children with PWS (33).  The use of physiotherapy, 
occupational therapy, speech therapy, cognitive therapy and dietetic services is a usual 
part of treatment to deal with muscle tone, feeding difficulties in infancy, over-eating in 
childhood, and learning difficulties.
Histiocytosis refers to a group of RDs resulting from an over production of histiocyte, a 
tissue macrophage part of the mononuclear phagocytic system responsible for tissue 
destruction and defense. Histiocytosis can be divided into three or more categories 
including Langerhans cell histiocytosis (LCH), non-Langerhans cell histiocytosis (Juvenile 
xanthogranuloma, Hemophagocytic lymphohistiocytosis, Niemann-Pick disease and Sea-blue 
histiocyte syndrome) and malignant histiocytic disorders (Acute monocytic leukemia, 
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Malignant histiocytosis and Erdheim-Chester disease). The individual prevalence varies
across different types. Overall prevalence is estimated at 1:200,000 predominantly in 
children. The EU prevalence of the LCH type is estimated to be 2:100,000 population (16). 
The disease attacks various tissues and organs (skin, bone, muscles, liver, lungs and 
spleen) and forms tumours in a similar manner to cancer, but is thought to be an 
autoimmune disease with a genetic component for some.  Treatment involves 
corticosteroids to suppress immune function, chemotherapy and radiotherapy, as well 
as physical therapy and breathing support. Niemann-Pick disease (NMD) is 
characterized by a number of progressive and debilitating (and fatal) neurological 
symptoms, including poor muscle co-ordination, impaired gait, and learning and 
cognitive difficulties.  Symptoms present early (0-12 years) with earlier onset 
associated with rapid disease progression.  The disease is exceptionally rare, with 67 
diagnosed cases in the UK (2008) (34) and Western European prevalence estimated at 
1:150,000 population (35).
EB is part of a group of rare hereditary skin diseases characterized by blisters forming 
on the skin spontaneously, or following minimal trauma. Due to a mutation in the 
keratin or collagen gene, the skin is extremely fragile, with 4 major sub-classifications.  
Disease severity varies from benign to deadly, with more severe forms affecting the 
internal gut linings and resulting in poor absorption and chronic malnutrition in 
addition to skin cancer development (36).  The prevalence of EB is 50 children per 
million births, with no racial or sex prejudices (37). In the EU, the prevalence is 
estimated to be 2.4:100,000 population (16).  The pain associated with EB has been 
described as third degree burns. Recent treatment developments include bone marrow 
transplants. 
<Table 1 about here>
3.2 Evidence on costs and availability of COI evidence
A total of 1654 article titles were initially screened (Figure 1). Of these, 253 abstracts 
were retrieved for further investigation. Studies reporting any COI data were included, 
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while studies not providing concrete data (e.g. estimates based on similar conditions) 
were excluded. Cost-effectiveness studies were only included if they reported 
information on the COI or components of specific types of health care, individual or 
societal costs. A total of 201 full-text articles were accessed for eligibility (including 
cited articles), and 77 studies were included in the study. There was an unequal 
distribution of studies over disease types, with the largest proportion of studies 
covering CF (n=29) and haemophilia (n=22). For the remaining diseases 0-8 studies per 
disease were identified, but, overall, COI study availability was limited across most of 
the study RDs (Table 2). The evidence collected indicates COI data availability in terms 
of total lifetime costs across four RDs (CF, DMD, FXS, haemophilia), and total annual 
costs and indirect total costs across five RDs (CF, haemophilia, JIA, histiocytosis, 
scleroderma). In the sections that follow, we present the available evidence.
<Table 2 about here>
Cystic fibrosis
In total, 29 studies were found to address COI aspects of the disease, making it the most 
studied disease out of the ten conditions selected. Lifetime treatment costs are 
estimated to be lower in older studies, as prevention of progression (physiotherapy, 
high fat diet plus enzymes) and medications (IV therapy) were not yet universally 
applied. Over twenty years ago Wildhagen et al. calculated Dutch lifetime costs per 
patient adjusting for survival and using a 5% discount rate to €287,591 (GBP 164,365 in 
1991)(38), while later estimates in Germany based on extrapolation of childhood costs 
suggested €477,280 (€396,000 in 1997)(15), close to the 1994 Israeli estimate of 
€374,173 (US$328,431 in 1993) which includes heart- and lung transplant at age 35
(39). More recent estimates incorporating advances in disease management suggest
lifetime costs in Germany are €858,604/patient, assuming a 39.7 year survival and a 3%
discount rate (40) (€824,159 in 2007), while American data suggest  €1,907,384
(US$2,335,699 in 2006) assuming 37 year survivali,(41).  The significant differences 
                                                       
i This estimate was generated by multiplying average annual medical cost of US$63,127/patient by life 
expectancy (37 years). No discount rate was applied.
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between these estimates are primarily due to inclusion of only outpatient costs in 
Germany, while the American study incorporated direct costs including medication and 
inpatient care (though unclear whether outpatient costs were included).
Per patient average total costs (direct plus indirect) depend on age, ranging from 
€16,307 at age 1-9 to €68,331 at age 30-39 (DKK94,150 and DKK394,518 in 1998)(42). 
Pauly estimated annual indirect costs at €8,814 (US$8,400 in 1996) based on incapacity 
to work, disability and premature death, corresponding to 60% of estimated direct costs
(43), while the US Office of Technology Assessment based an estimate of €11,543
(US$11,000 in 1996) on time invested by patients and relatives in CF therapy, 
corresponding to 94% of direct costs (44). Including time lost from paid labour, unpaid 
labour and leisure time for both the caregiver and patient as well as employers cost for 
paid sick leave, indirect costs of as much as €1,617 (CA$2,026 in 2005) per 28 days 
have been reported (€21,075 per year)(45).
The estimated average annual direct treatment costs range between €7,108/patient in 
Canada (CA$7,524 in 1997)(14) and €51,551/patient (US$63,127 in 2006) in the USA
(41) with a reported 7-fold difference between mild and severe cases (46), and younger 
children generally at the lower end of the range at €10,989 (US$12,008 in 2002)(47).  
More recent estimates, although lower, may be a more accurate reflection of current 
treatment costs due to significant advances in CF treatment and prevention of serious 
infections. Baltin et al. estimate annual CF treatment in Germany at €17,938/patient 
(€17,219 in 2007), increasing to €22,692/patient (€21,782 in 2007) with IV therapy
(40), while Huot et al. arrive at €25,781/patient (€22,725 in 2003) in Franceii.
Concomitant Pseudomonas infection tends to increase medical costs significantly (15, 
48) but to a lesser extent with early eradication treatment (49).
The components of treatment costs differ across studies. Baumann et al. provide a 
comprehensive cost breakdown: of total annual care costs (€28,913 [€23,989 in 1997]), 
outpatient and inpatient care account for 59% and 41% respectively – 47% of total 
expenditure was on outpatient drugs.  A more recent French study reported annual 
inpatient costs of €5,730/patient (€5,051 in 2003), while home care costs were even 
higher at €20,051/patient (€17,674 in 2003). Drugs accounted for 45% of the total cost, 
and hospital care for 15% (2000) to 22% (2003)(50).  An alternative breakdown based 
                                                       
ii This paragraph does not include direct cost screening estimates.
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on American 2006 health insurance data estimated costs at €39,278/patient 
(US$48,098 in 2006), of which 34.4% was for inpatient care, 27.2% for outpatient care 
and 38.4% for medications (51).  An older Medicaid breakdown (1993) found inpatient 
costs were 47%, physician care 8%, private nursing 12%, outpatient care 5%, drugs 
12%, medical equipment 8%, other 8% (52). The costs attributable to hospitalisation
and drugs can be modulated by considering preventive drug regimens (53, 54) and by 
implementing home-based intravenous infusions (55, 56).
Drugs for CF tend to account for a large proportion of expenditure across settings. 
Schreyogg et al. considered inpatient hospitalization costs of 131 German CF patients by 
disease severity and found mean total cost was €8,098/patient (€7,326 in 2004)iii(57), 
while severe cases cost 78% more than mild cases.  Aside from overheads (staff costs 
for non-patient care and ‘other’), drugs formed the largest component, particularly in 
severe cases. Eidt et al. found medication costs in Germa  CF outpatient clinics were 
approximately €23,019 (€21,604 in 2006)(58). New rhDNase therapy is particularly 
costly (€9,705 [CA$10,110 in 1996])(14) but can reduce overall direct cost (59), as are
IV antibiotics given as either in- or out-patient (€4,045 [€3,565 in 2003]) (50). In 
earlier work pancreatic enzymes and antibiotics accounted for approximately 50% of 
total lifetime costs (39). The highest reported figure was 57% of direct costs 
attributable to drugs (60), and the lowest at 9% was recorded in an insurance claims 
based study from 1994 where inpatient care accounted for the majority of direct costs 
(59-81%) (61).
Only one study examined ‘non-healthcare costs’ associated with CF (including non-
hospital medical care, domestic help, special facilities etc.), and estimated home-care
costs to be approximately 50% of total medical and non-medical lifetime costs. Total 
average non-hospital costs of care were estimated at €10,826 (GBP6,657 in 1993)(13).  
In other studies, home-care has been estimated to be both significantly more expensive 
than inpatient care per patient (€12,838 [€10,865 in 2001] vs. €2,316 [€1,960 in 
2001]) and significantly less expensive than inpatient care (€18,933 [GBP13,528 in 
2002] vs. €31,642 [GBP22,609 in 2002]iv). Differences may result from diverging 
methodologies, as Elliott et al. considered identical cost categories (antibiotics, 
                                                       
iii In this case, total cost per case is specific to hospitalisation, not to treatment overall.
iv Patients were  classified as receiving care either at home or in hospital, based on the location in which they 
received >60% of their treatment, over the course of one year.
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laboratory tests, clinic visits, days in hospital) but classified patients according to the
majority (>60%) of treatment received in either location (62), while Horvais et al. 
directly segregated costs as either ‘inpatient’ or ‘outpatient’ (63).
Four studies estimated the costs/benefits of population wide screening, and found benefits 
generally outweighed the cost. For example, cost of screening in Denmark was €322,953
(DKK1,864,594 in 1998) while the net present discounted value of a CF case averted was 
€368,833 - €520,796 (DKK2,129,484 - DKK3,006,858 in 1998) depending on the median 
life expectancy of patients (30 or 40 years) (42), largely echoing previous work in the USA 
where treatment savings offset 74-78% of the cost of a screening programme (64). As a 
further benefit, average cost of treatment of children with CF diagnosed by screening have 
been shown to be lower (47). 
Duchenne muscular dystrophy
Only three studies (the Netherlands, USA and Canada) reported treatment costs of DMD, 
all outdated.  The Dutch study (65) identifies only total lifetime costs (1994 data).  The 
American study (66) provides a breakdown of some direct treatment costs (equipment 
and rehabilitation) but a total cost figure is not calculated (1983 data).  The Canadian 
study examines the cost-effectiveness of DMD screening and provides some estimates 
as costs of averting DMD (1988 data) (67).  
The lifetime discounted (5%) cost of DMD treatment was estimated at
€541,593/patient (US$487,723 in 1994), however it is unclear how these costs were 
estimated (65). 
Direct cost estimates are incomplete.  The average annual equipment cost is between 
€1,322 (US$800 in 1983) and €1,653 (US$1,000 in 1983), including wheelchairs (55%), 
heavy equipment (ramps, lifts, hospital beds) (13%), respiratory equipment (11%), 
footwear (9%), spinal orthoses (7%) and seating apparatus (5%) (66).  Total outpatient 
rehabilitation costs are €1,983/patient (US$1,200 in 1983).  Since 1983, supportive 
technologies including wheelchairs have advanced significantly in technology and cost, 
meaning these costs are likely an underestimate today. No information is available on 
the cost of drugs.
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The cost of averting a single case of DMD is estimated to be €206,051 (CA$172,000 in 
1988), with an incremental cost per case averted of €99,552 (CA$83,100 in 1988) (67).
Fragile X syndrome
Only a few of the studies stated which costs were included in lifetime treatment costs. A 
few (68, 69) commented that the most accurate estimates are those from Wildhagen et 
al. which are age- and sex- adjusted for survival and use a 3% discount rate resulting in
a lifetime estimate of €980,057 (US$957,734 in 1995) for a male and €546,112
(US$533,673 in 1995) for a female (70). Per annum direct care costs are at least 
€31,050/patient (GBP20,000 in 1995)(68), and recent American data reveal total out-
of-pocket  (OOP) expenditures of €13,873/patient (US$17,476 in 2007), of which 19% 
is spent on drugs. Significantly, median OOP expenditure was €1,508/patient (US$1,900
in 2007) indicating high expenditure among a small number of families (71).  This study
also suggests therapy (undefined), transportation and medication are the main 
components of OOP care costs.
Haemophilia
In total, 22 studies were found to address COI aspects of the disease, making it the 
second most studied disease out of the ten, following CF.
Only one study (Mexico) estimated total lifetime discounted (5%) cost of hemophilia 
treatment, which differed by type of treatment from €133,024 (MXN1,408,478 in 2000) 
for cryoprecipitate factor treatment, to €258,025 (MXN2,731,997 in 2000) for 
concentrate factor treatment (72). Total annual cost was reported in two studies, 
ranging from €1,101 (€953 in 2002) in Sweden for on-demand (OD) treatment (73) to 
€178,796 (€147,939 in 2000) in Sweden for prophylactic treatment (74), though not all
prophylactic regimes reported such high costs (73). 
Indirect costs associated with hemophilia were negligible in some cases (€836 [DM683 
in 1996] per patient, 2.8% of direct costs) (75) but significant in others, amounting to 
47% of direct costs in one study, though there were significant variations between 
countries (73). One study comparing on-demand with prophylactic treatment estimated 
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indirect costs could be up to 88% (€37,582 [€31,096 in 2000]) of direct costs in on-
demand treatment, though the figure was much lower (12%, €15,716 [€13,004 in 
2000]) in prophylactic treatment (74).
Annual average direct medical costs range from €1,042/patient (€902 in 2002) (73) to 
€275,398/patient (€215,221 in 1999) (76) when inhibitors are present, to €745,376
(US$ 884,266 in 2005) when inhibitors are present and extremely high cost patients are 
included (over US$ 1 million per year) (77). High cost outliers also drove up the mean 
drug cost in a separate study, where median cost was found to be almost identical 
between inhibitor/no-inhibitor patients but the mean for inhibitor patients was 76% 
higher (78). 
An American evaluation of a haemophilia disease management programme estimated 
baseline annual costs were €144,417/patient (US$161,441 in 2003) of which the 
majority (91%) was outpatient factor (drug) use and 8% attributable to hospitalisation. 
When the disease management program was implemented, costs fell to
€99,713/patient (US$118,293 in 2005) (79). A Canadian study resulted in substantially 
lower costs, €53,172/patient (CA$62,292 in 2002) (80), of which Factor VIII medication 
was the primary component (CA$59,910) with hospitalization costs (including drugs, 
nursing care and inpatient stay) making up almost all of the balance (CA$1,832). 
American, Italian and German studies also indicate anti-haemophilia drugs (including 
factor VIII) make up a significant proportion of total treatment costs (93.8%, 98.8% and 
99.6%, respectively) (75, 76, 81), up to €275,398 per year (€17,935 per month in 1999)
(76). The mean cost of drugs per patient kilogram per year was estimated to be €2,080
and €3,980 (€1,626 and €3,110 in 1999) for patients without and with inhibitors 
respectively (82), and elsewhere was reported per patient to be €80,780 and €165,408
(US$80,000 and US$141,000 in 1998), respectively (78).  
The cost of drugs has been estimated per bleeding episode for activated prothrombin 
complex concentrate (aPCC) and recombinant activated factor VII (rFVIIa) with 
conflicting results. One study (Brazil) found aPCC treatment was more costly than 
rFVIIa per episode (both for rFVIIa alone and total treatment cost), with aPCC costing
€6,935 (US$8,227 in 2005) compared to €5,909 (US$7,010 in 2005) for rFVIIa (83).  In 
contrast, an American study estimated aPCC treatment cost at €17,702 (US$21,000 in 
2005), while initial treatment with rFVIIa cost €28,154 (US$33,400 in 2005) per 
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episode (84). Total treatment cost with home administration has been shown to cost 
less than hospital administration (72).
Cost of inpatient drugs per patient was shown to be significantly influenced by a 
number of factors. The median cost of drugs for HIV positive patients was 
approximately 4 times higher than HIV negative, surgery linked to haemophilia was 
approximately 10 times higher than non-surgical use, costs of adults (18 years or over) 
were approximately 4 times higher than children, and presence of inhibitors or severe 
disease were approximately 2 times higher than no inhibitors or mild disease (85); 
however other evidence suggests there is no difference in median drug cost between 
patients with/without inhibitors, with a small number of high-cost patients driving up 
the mean cost for patients with inhibitors (86). A French study estimated the annual 
mean drug cost of treating a patient without inhibitors at €74,240 (€59,887 in 1997) 
and with inhibitors at between €67,221 (€54,226 in 1997) and €231,175 (€186,482 in 
1997) depending on whether the patient was a high or low responder (87). Infection 
with HIV or HCV, apart from clotting factor, is also known to be associated with 
increased costs for prescription drugs, inpatient- and outpatient services, which is of 
importance due to the many infections occurring prior to blood screening in the 1980s
(88, 89).
As an external factor, time to treatment has been shown to have a statistically 
significant upward effect on both total cost and number of doses required for resolution. 
As patients generally live further from hospitals than from outpatient clinics, both time 
to treatment, time to resolution and total cost was 3-4 times higher in hospitals than in 
outpatient or home treatment settings (90). 
Schramm et al. examined costs incurred by patients in both prophylaxis and on-demand 
(OD) groups in a multi-country (France, Germany, Italy, Netherlands, Sweden, UK) 
analysis (73). Both France and Italy found the total cost of treating patients in the 
prophylaxis group was significantly higher (around 3.5 times, 3.7-4.1 times for direct 
costs) than in the OD group, while in Germany prophylaxis group costs were lower than 
the OD group. Hospitalisation costs were highest in the French OD group (64% of direct 
costs). A similar study by Carlsson et al. also found on-demand treatment was less costly 
than prophylaxis treatment (€62,264 [€51,518 in 2000] vs. €180,542 [€147,939 in 
2000] respectively) (74), though the actual cost estimates were substantially higher 
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than any of those outlined by Schramm et al. The greatest treatment cost was for Factor 
VIII: 74% in OD patients and 94% in prophylaxis treatment. There is however evidence 
that quality of life is greater in patients on prophylactic treatment, and that prophylaxis 
results in fewer problems with work and other activities of daily living (75). 
There appears to be no significant variation in hospitalisation costs between type A and 
B haemophilia (91), but annual treatment costs may vary with age, as German evidence 
shows paediatric patients, both with and without inhibitors, cost much less to treat than 
adults (by more than 4 times in both groups) (92).
Comparing mean and median costs, it is evident some of the high cost cases cause the 
mean cost to be significantly higher than the cost for a typical patient (77, 78, 82). 
Juvenile idiopathic arthritis
Across the eight costing studies discovered and examined, study perspective, sample 
size (and mean age) and data reference year varied significantly.  Six of the studies 
examined the economic impact associated JIA, while one study considered the impact on 
total cost of etanercept treatment (93) and another examined the cost-effectiveness of 
JIA hydrotherapy (94); although these focused primarily on the cost-effectiveness or 
effect on treatment cost of specific therapies, they are included here because they 
provide a comparison for standard therapies.
The mean annual total cost is estimated between €4,143/patient (€3,471 in 1999) (95)
and €29,613/patient (US$33,171 in 2000) (93, 96).  Substantial variation is evident 
between sub-groups, however, there is a suggestion that a small proportion of patients 
(<12%) are responsible for 80% of overall costs, with a small number of inpatient cases 
accounting for 53% of direct costs (95). A small proportion of direct cost (3%) were due 
to devices and aids, and 14% attributable to medications (95).
Loss of income for parents was generally taken as a measure of indirect costs. In 1999, 
these costs were estimated at €1,870/patient annually (€1,571 in 1999), 86% of direct
costs. In 2008, the same authors reported €274/patient annually (€270 in 2008), 6% of 
direct cost (95, 96).  This reduction over time may be due to benefits of improved drug 
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therapy (i.e. TNF-alpha inhibitor etanercept), improving patient outcomes and enabling 
carers/parents to return to work. Other estimates in recent years are comparable to the 
latter, at €668 (CA$837 in 2005) per year per patient, or 28% of direct costs (22), 
approximately €142-288 (GBP99-200 in 2000), 5-11% of direct costs (94) and €274 
(€270 in 2008) or 6% of direct costs (96). Etanercept treatment was directly shown to 
reduce the indirect costs from €750 (US$840 in 2000) to €373 (US$418 in 2000) per 3-
month period, 13% to 6% of direct costs, when added to the standard treatment (93).
Costs at all levels are substantially skewed towards active patients (those not in 
remission).  For example, the mean total cost of active JIA patients at €6,763 (€5,681 in 
1999) are more than seven times those in remission at €931 (€782 in 1999) (95). There 
is also substantial variation by subgroup with highest costs in patients with enthesitis-
related, systemic JIA, extended oligoarthritis and polyarthritis (RF+v)(95, 97), for whom 
the total treatment costs are almost double all JIA patients (95).  
Furthermore, the introduction of new pharmaceutical therapies significantly affected 
both direct and indirect treatment costs according to Haapasaari et al. (2004) who 
estimated etanercept introduction resulted in an increase in direct annual per patient 
costs by €3,767 (US$4,220 in 2000), but a reduction in indirect costs by 50% 
(€1,507/patient annually [US$1,688 in 2000]) as a result of lower productivity losses 
accruing to parents for escorting th ir child to treatment (93).  Total annual median 
costs were estimated to rise by €2,425 (US$2,716 in 2000) with etanercept treatment.
Minden et al. performed comparable analyses in 1999 and 2008. While direct costs 
more than doubled over the period, indirect costs fell drastically, yielding a total 
differential of only €4,132 to €4,728 between 1999 and 2008 (95, 96)
Several studies estimate the mean annual direct cost of JIA per child, the most recent 
being €4,464 (€4,403 in 2008) (96).  Other estimates range from €2,202 (GBP1,649 in 
2005) (97) (secondary care provider perspective) with 11% for drugs, to €9,273
(US$7,904 in 1992) (98) (health care system perspective) of which 22% was for 
inpatient care. The highest estimate was for etanercept treatment at €27,603
(US$30,919 in 2000) (93), where drugs accounted for up to 54% of direct costs. Direct 
costs in turn account for 6-55% of total costs, depending on the study (95, 96).  In 
                                                       
v Rheumatic factor seropositive.
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addition to calculating costs from a societal perspective, Allaire et al. (1992) estimated 
the mean annual family borne costs as €1,788 (US$1,524 in 1992), including OOP 
medical costs (46%), salary loss (22%) and non-medical expenses (32%) (98). 
The most recent estimate suggests healthcare costs comprise 95% of total direct costs
in 2008, unchanged from 1999 (95, 96).  Approximately 60% of healthcare costs are 
attributed to outpatient care with inpatient care making up the remaining 40%. 
Medication accounts for 47% of total annual direct costs (€2,097/patient [€2,069 in 
2008]), physician visits 7% and non-physician visits 3% (96).
While medication comprises the largest portion of healthcare costs for JIA patients in 
Canada (43%), with specialist care only 12% of costs, this relationship is inverted in the 
UK with the specialist care cost being the most substantial cost component (45%), while 
medication represents only 11% of healthcare costs (97).  This is potentially the effect 
of etanercept, or other IFN-alpha inhibitors, coming onto the market and being 
approved for reimbursement faster in Canada than in the UKvi, raising the drug 
component of treatment costs (substantially), but lowering specialist costs because of 
improved efficacy of treatment. 
A number of studies examined costs and cost-effectiveness of JIA drug treatments, 
focusing primarily on the IFN-alpha inhibitor etanercept.  Brunner et al. (2004) 
estimated the mean annual costs of methotrexate therapy at €6,997 (US$8,030 in 
2004), etanercept treatment at €7,728 (US$8,870 in 2004) and combination therapy 
(methotrexate and etanercept) at €11,005 (US$12,630 in 2004), accounting for 26-54% 
of total mean cost (99). Earlier studies estimated the cost of drugs somewhat lower at 
€619 (US$528 in 1992), or 7% of total direct costs (98).
Epps et al. (2005) indicate anti-TFN therapy annual costs (including etanercept) is 
approximately €11,473/patient (GBP8,000 in 2000) (94). A systematic literature 
review by Cummins et al. (2002) cites evidence that the annual cost per JIA patient is 
€12,590 (GBP8,996 in 2002) resulting in a discounted cost/QALY (Quality Adjusted Life 
Year) of €22,507 (GBP16,082 in 2002) (100).
                                                       
viIn England (2002), NICE issued a narrow reimbursement of etanercept in children (4-17y) with active poly-
articular-course JIA with poor response to methotrexate. 
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Mucopolysaccharidosis type I and type VI (MPS I, MPS VI)
Only one study, a systematic review, was found which detailed costs and effectiveness of 
enzyme replacement therapies for MPS I.  Information from electronic databases, 
pertaining to the medical costs of 41 patients in the UK, was collected from inception of 
treatment to mid-2004 and combined with information provided by clinical experts.
Likewise only one study for MPS VI was identified.  Although it focuses on the process of 
marketing authorization and reimbursement for rhASB, some cost discussions are 
included.
The annual drug cost of treatment with Aldurazyme (laronidase) was differentiated by 
age with €130,451/child (GBP95,752 in 2004) assuming a weight of 20kg, and 
€456,581/adult (GBP335,134 in 2004) assuming a weight of 70kg.  Based on the full 
patient cohort (n=41) on the UK Society for Mucopolysaccharide Disease registry, the 
total national annual cost for drugs alone for MPS I is estimated to be GBP5.1million 
(101).  No additional costs of treatment were supplied.
Schlander & Beck (2009) estimate the annual cost of rhASB for MPS VI to be €158,295
(€150,000 in 2008) to €474,885(€450,000 in 2008) per patient (depending on the 
patients’ weight), with mean cost per patient per year of €369,355 (€350,000 in 
2008)vii (28) assuming a mean weight of 25kg. 
Scleroderma (systemic sclerosis)
In total four studies were identified that addressed lifetime, direct and/or indirect costs, 
and one study that quantified specific drugs/therapies. The aggregate annual costs of 
treating scleroderma are significant. Recent work by Bernatsky et al. (2009) estimate 
the total scleroderma treatment cost for all patients in North America is €1.5bn 
(US$1.9bn in 2007), and €3.3bn (€3.1bn in 2007) in Europe (102).  Other American and 
                                                       
vii This is based on an assumed mean weight per patient of 25kg, a recommended dose of 1mg rhASB/kg 
bodyweight/week and a cost of €1,400 (GBP982) per vial.
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Italian estimates suggest total treatment costs are €1.6bn (US$1.46bn in 1994) (103)
and €1.4bn (€1.2bn in 2001) (104) respectively. 
Annual mean total costs per patient vary across countries.  Minier et al. (2010) estimate 
the total cost in Hungary at €12,032 (€9,619 in 2006) including direct non-medical 
costs (home remodeling, transportation etc.) and productivity loss (105), Canadian 
costs are €14,133 (CA$18,453 in 2007) (30) and in Italy €13,502 (€11,074 in 2001)
(104).
Three studies estimate indirect costs, however there is little uniformity in what is 
included in this category.  Recent Hungarian estimates were €6,742/patient (€5,390 in 
2006), of which 98% was productivity loss by disability pensioners and 2% was sick 
leave (105).  Mean annual indirect costs were €10,275/patient (CA$13,415 in 2007) in 
Canada, of which 40% was lost productivity from paid labour and 60% from unpaid 
labour (30). American indirect costs were differentiated as mortality losses 
€2,038/patient (US$1,835 in 1994) and morbidity losses of €9,319/patient (US$8,392
in 1994) for a total of €11,357/patient (103).
Recent estimates of direct medical cost of scleroderma are €4,128 in Hungary (€3,300 
in 2006), of which hospitalization was the largest component (82%) and drugs 
accounted for 12% (105). Canadian total direct healthcare costs were €3,858 (CA$5,083
in 2007), of which medication was the largest single component (31%), followed by 
acute-care hospitalization (28%), healthcare professional visits (15%) and diagnostic 
tests (14%) (30).  Wilson et al. found a distribution in 1994 of 45% and 22% for 
hospitalization and drugs respectively out of total costs of €4,926 (US$4,694 in 1996). A 
small proportion (0.3-4%) of direct costs were spent on assistive devices (30, 105), 
though home remodeling also accounted for a sizeable proportion (20%) of non-
healthcare direct costs (105). Across these studies, direct costs generally account for
approximately 1/3 of total costs. 
Only Minier et al. (2010) provides estimates of average annual direct non-healthcare 
costs totaling approximately €1,162/patient (€929 in 2006), and comprising of 
transportation (ambulance travel, travel vouchers) (49%), informal care (26%), home 
remodeling (20%) and transportation (non-reimbursed) (5%) (105).
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Prader-Willi syndrome
No studies with information on the COI related to PWS were found during the study 
period.
Histiocytosis
Only one study was identified explicitly quantifying costs of any of the histiocytosis 
syndromes, focusing on Niemann-Pick disease (NPD) with a comprehensive breakdown 
of direct (medical and non-medical) and indirect costs (34).  
Total annual average costs of treatment for patients with NPD were estimated at 
€49,947/patient (GBP39,168 in 2007), comprised of direct medical costs (46.2%, 
€23,066 [GBP18,088 in 2007]), direct non-medical costs (24.1%) and indirect costs 
(29.7% of total or 64% of direct costs).  Direct medical costs were made up 
predominantly of home visit (72.5%) and residential care (15.7%), with medications 
and hospitalisations accounting for only 1.6% and 1.2% respectively. Special education 
costs formed the primary component of direct non-medical costs (97%, €11,691
[GBP9,168 in 2007]), calculated as the incremental cost of specialist education (over 
and above the costs of standard school attendance borne by society for all children).
Annual indirect costs were estimated to be high.  Per patient productivity losses due to 
reduced working hours, absenteeism and unemployment for both patients and carers 
were estimated at €12,762 (GBP10,008 in 2007) and €2,081 (GBP1,632 in 2007) 
respectively, totaling €14,842/patient annually. From a narrower National Health 
Service (NHS) perspective, excluding indirect costs and OOP payments, the mean annual 
cost was €22,969/patient (GBP18,012 in 2007).  Mean annual OOP payments made by 
families and patients were estimated at €447 (GBP351 in 2007), comprising non-
prescription medications (19%), other health services (3%) and travel costs (78%)
(34).
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Epidermolysis Bullosa
Overall, one study was identified that addressed cost-effectiveness aspects of screening 
and one that discussed specific treatments/therapies. One study examines the cost 
effectiveness of the ‘Kozak protocol’ in treating nine children in a single hospital in 
Ontario, Canada (1980 data)viii (36). A response to this study by Ramsay (1984) 
indicates some serious discrepancies in the cost data, specifically which costs from the 9 
patients actually pertained to EB (106).  As a result, these costs have not been discussed 
in any depth. High-dose intravenous immunoglobin (hdIVIg) has been used to treat a 
few cases of EB, however its clinical efficacy is unclear as this treatment was not 
undertaken within a controlled trial setting (107).  No other studies were found related 
to costs and EB.
<Table 3 about here>
4. Discussion 
4.1. Evidence and policy implications
In this review, we identified 77 studies that provide some level of information on the 
economic burden of ten selected RDs. An overall summary of the cost results is shown 
in Table 3. For some conditions (PWS and EB) no COI information was available despite 
relatively high prevalence (see Table 2). For other conditions (DMD, MPS I and VI, 
histiocytosis, FXS, scleroderma) COI information was very limited, and with the 
exception of MPS for which rhASB has undergone clinical trials as a treatment, none of 
the conditions for which little COI evidence was found are associated with a specific 
pharmaceutical treatment. Rather, care is based on the alleviation of symptoms, 
management of complications and other supportive care. 
In contrast, pharmaceutical compounds are available specifically for CF (DNase) and for 
haemophilia (clotting factors), which between them account for 47 of the 77 studies 
included in this review. Overall, the availability of evidence on the economic burden of 
                                                       
viii It is unclear from the paper what the Kozak protocol entails, or what the baseline/control therapy included.
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RDs appears to be correlated with the availability of specific therapies rather than, for 
instance, the rarity or severity of the disease itself (Figure 2). 
For the conditions with the most detailed evidence (CF, haemophilia and JIA) there are 
some common features. The distribution of costs over different patients tends to be 
skewed with either a small proportion of patients accounting for a large proportion of 
resource utilisation (82, 95, 96) or particular subgroups of patients incurring higher 
costs. For example, haemophilia patients with HIV were four times as expensive to treat 
as HIV negative (85), and seropositive polyarthritis was five times more expensive to 
treat than persistent oligoarthritis both in total and direct cost estimates for JIA patients
(96).
In most studies reviewed in this study, the median cost tended to be lower than the 
mean, consistent with a small proportion of high-cost patients driving up average costs
therefore suggesting a positive skew. As a summary of economic burden we have 
reported the mean rather than the median since this better incorporates the variation in 
severity among patients. When interpreting the results, therefore, it should be taken 
into account that the typical (median) patient will likely incur lower costs than reported 
here, while a small number of patients will incur substantially higher costs. 
Apart from the direct cost of treatment borne either by insurance organisations or 
patients and families privately and, in most cases, on an out-of-pocket basis, the indirect 
COI signifies the burden on the affected patient or carer, and is higher for more 
debilitating conditions. When comparing the indirect cost to direct cost we find that the 
former can be significantly higher, e.g. up to 216% of direct costs in the case of
scleroderma. All evidence on scleroderma suggests indirect exceeding direct costs (30, 
105), but in all other conditions where evidence is available the indirect costs amount to 
less than direct costs. In some cases, direct and indirect costs can be traded off against 
each other, as in haemophilia care, where patients treated prophylactically incur higher 
direct costs as a result of factor use but avoid more hospitalizations and thus 
disruptions to their daily life and work pattern (75). However, most conditions 
examined here do not have an effective prophylaxis regime, as patients are continually 
affected by symptoms and must be managed on a regular basis. Importantly we note 
that evidence on indirect cost was only available for four out of ten diseases, and that 
the COI from a societal perspective for most of the diseases examined here, therefore, is 
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not known. As discussed earlier, indirect costs may account for a significant proportion 
of overall costs and as such this lack of evidence constitutes an important shortfall.
It is clear that the evidence base for the COI at individual, health system and societal 
level is fairly poor when it comes to understanding the pressures faced by both 
individuals, families and society in the context of RDs. However, the importance of RDs
has long been recognised in the EU, reflected in various EU funded strategic activities, 
including cooperative research in the field of Health and ERA-NET programmes as well 
as a priority action area in the Health Programme work plan. At a higher level, the 
European Union Committee of Experts on Rare Diseases (EUCERD) acts as a 
coordinating body for member states in planning and implementing activities related to 
RDs. The BURQOL-RD project aims to provide new tools and knowledge on RDs
unavailable in the EU, including socio-economic burden and health related quality of life 
for patients and their caregivers. Other activities under the EU 7th Framework 
Programme (FP7) and beyond are also concerned with RDs, particularly relating to 
clinical guidelines (Rare Best Practices) and the use of Health Technology Assessment in 
evaluating rare diseases (Advance HTA), which also include methodological 
improvements in the way evidence is produced and utilised by researchers and 
decision-makers. 
The non-availability of COI evidence reflects the rarity of the ten diseases investigated. 
In constrast to other disease areas such as cancer and diabetes, the impact of these RDs
on patient population and their carers is not well documented. The results of this study
suggest that more could be done to study the economic consequences of RDs on society, 
not only accounting for direct medical costs but also for indirect costs relating to 
productivity losses given their significant magnitude. At a broader level, these results 
also point towards the need for society to invest in researching and developing new
therapies, and allocating resources to ensure patient access. Nevertheless, it should be 
borne in mind that such decisions are always associated with important opportunity 
costs relating to allocation of resources elsewhere, either for the discovery and 
development of new treatments or the access to and provision of health care. The 
former is already reflected through the Orphan Medicinal Products Regulation 
(Regulation (EC) No 141/2000), which provides a set of incentives relating to market 
exclusivity, protocol assistance and access to the centralised Procedure for Marketing 
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Authorisation, to encourage the R&D and marketing of orphan medicines and has led to 
about 120 collaborative research projects relating to RDs through funded research
activities on innovation and technological development. With regards to resource 
allocation and access to health care, most national HTA agencies have special 
frameworks in place to facilitate and enable the coverage of medical technologies 
treating RDs, taking into account their small market size, high severity of disease and 
poor cost-effectiveness. The findings of this study confirm the European Commission’s 
Communication on Rare Diseases, aiming to set out an overall strategy to support 
Member States in diagnosing and treating rare disease patients, but also the Council’s 
recommendation on action in the field of RDs calling for the implementation of national 
strategies (108). 
4.2 Challenges, limitations and ways forward
A number of methodological questions and limitations need to be raised in connection 
with the study, its findings and their meaning. Although many of them lie outside the 
scope of this study they should be acknowledged and earmarked for further 
investigation. Most of them relate to the comparability of costing evidence across 
settings, individual disease areas and over time. First, despited having facilitated 
comparisons across countries and therapeutic areas by harmonising currencies and cost 
years, one limitation of this study is the wide variety of costing methodologies used, 
including differences in discounting, assumptions relating to life expectancy and other 
treatment factors, and differences in the categories of costs included. Indirect costs, 
largely based on measures of productivity, also differ between studies. This limits the 
direct comparability of costs between RDs, and, consequently, the use of such 
information in priority setting.  Second, the approach used to compare costs across 
countries through exchange rate-adjusted currency units does not necessarily address 
differences in income across countries. Other more advanced approaches, such as 
adjusting figures to absolute GDP differences and variations in the GDP percentage 
spent on health across the different countries could be adopted instead, aiding more
robust conclusions on the magnitude of costs, their differences and comparability 
across different settings. A third limitation is the varying discount rates applied when 
calculating lifetime economic burden. Although in most cases lifetime cost figures are 
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estimated by considering the respective life expectancy of the disease, varying discount 
rates can be applied across different studies therefore limiting the comparability of the 
results. A further limitation is that, strictly speaking, intangible costs relating to 
suffering of patients and carers are not considered as “costs” but, instead, as quality of 
life dimensions and, therefore, are not addressed by the current study. Future research 
might want to adopt a broader perspective and capture these costs to the extent 
possible. A final limitation is the relatively small sample size in most rare disease COI 
studies, which in many cases include approximately 100-300 subjects per study but 
often less than 100 subjects, a corollary of the nature and prevalence of the diseases 
studied. There was a relatively strong country bias towards the United States and 
Canada, which accounted for 21 and 9 studies respectively, though Germany, UK, France 
and Netherlands also accounted for 11, 10, 6 and 5 studies each, respectivelyix. The 
above limitations suggest that future research and priority setting in this area would 
benefit significantly from a harmonised framework for COI studies, conceptually similar 
to the Organisation for Economic Cooperation and Development (OECD) System of 
Health Accounts (109) applied for health systems more broadly.
<Figure 2 about here>
5. Conclusions
Although methodological variations prevent any detailed comparison between 
conditions, most of the rare diseases examined in this study are associated with 
significant economic burden. Indirect costs associated with loss of productivity in most 
cases approach or exceed the level of direct costs. The level of evidence available is 
highest for conditions that have specific pharmaceutical treatments available and is not 
necessarily associated with disease rarity. The study raises awareness about the lack of 
research on the socio-economic impact of rare diseases, which can be substantial, as 
well as methodological issues related to the comparability of the available evidence 
across borders which need to be addressed in future research.
                                                       
ix Italy: 3, Israel: 2, Brazil: 1, Denmark: 1, Finland: 1, Hungary: 1, Mexico: 1, Turkey: 1, Europe: 1, 
Norway/Sweden: 1
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Figure 1. Literature Search Flow Diagram for COI studies across the ten study RDs
Figure 1 caption: literature search flow diagram showing the number of articles in each 
stage of the literature review  
# of records produced through 
databases searches
N = 1654
# of abstracts retrieved
N = 253
# of full-text articles accessed
N = 201
# of studies included in analysis
N = 77
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Table 1: EU-wide disease prevalence across the ten study RDs
CF1 DMD1 FXS1 HAE1 JIA1 MPS1 SCL1 PWS1 HIS1 EB1
Prevalence
1:2,500 –
3,600 
newborns (13-14)
1:3,600 
male 
infants (18)
1:3,600 
males; 
1:4,000 
– 6,000 
females
(20)
A: 
1:5,000 –
10,000 
males
B: 
1:20,000 
– 34,000 
males (21)
8-
150:100,00 
children (22)
Type I 1:100,000; 
Type II 
1:250,000; Type 
III 1:50,000 to 
1:280,000; 
Type IV 1:75,000; 
Type VI 
1:250,000 (23-27)
74:100,000 
women; 
13:100,000 
men (30)
1:22,000 
newborns
(32)
1:150,000 
(NMD) (35) 5:100,000
(37)
Prevalence 
(per 
100,000
population) 
(16)
12.6 5.0 20.0 7.7 5.0 3.0 (all types) 42.0 1.6 2.0 (LCH) 2.4
Note: 1 CF=Cystic Fibrosis; DMD=Duchene Muscular Dystrophy; FXS=Fragile X Syndrome; HAE=Haemophilia; JIA=Juvenile Idiopathic 
Arthritis; MPS=Mucopolyssacharidosis; SCL=Scleroderma; PWS=Prader-Willi Syndrome; HIS=Hystiocytosis; EB=Epidermolysis bullosa
Source: The authors.
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Table 2: Availability of COI evidence across the ten study RDs
CF1 DMD1 FXS1 HAE1 JIA1 MPS1 SCL1 PWS1 HIS1 EB1
Total number of cost-of-illness studies
Total, lifetime, direct, indirect 
cost
18 2 5 8 6 1 4 1
Patient sub-groups 12
Specific drugs/therapies 6 2 1 1 1 1
Other cost-related studies
Screening 5
Cost-effectiveness 1 1 1
Total studies 29 3 5 22 8 2 5 0 1 2
Note: 1 CF=Cystic Fibrosis; DMD=Duchene Muscular Dystrophy; FXS=Fragile X Syndrome; HAE=Haemophilia; JIA=Juvenile Idiopathic 
Arthritis; MPS=Mucopolyssacharidosis; SCL=Scleroderma; PWS=Prader-Willi Syndrome; HIS=Hystiocytosis; EB=Epidermolysis bullosa.
Source: The authors.
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Table 3: Direct, indirect and total costs related to the ten study RDs (€, 2010)
Total cost 
(€, 2010)
Indirect costs 
(€, 2010)
Direct medical costs  
(€, 2010)
Proportion of direct  costs
(per patient, annual)
Disease1
Lifetime Per patient, annual Per patient, annual 
(% of direct cost)
Per patient, annual Drugs Equipment, 
devices, aids
Inpatient care
CF
287,591-1,907,384 (15,38-
41)
16,307 - 394,518
(a)(42)
8,814-21,075 
(60-94%) (43-45)
7,108 – 51,551 (b)(14-15,40-41,46-
50) 9-57%
 (14-15,50-61) n/a 15-81% (15, 50-61)
DMD 541,593 (65) n/a n/a 1,983 (66) n/a 67-83% (66) n/a
FXS 546,112-980,057 (70) n/a n/a >31,050 (68) 19% (of OOP) (71) n/a n/a
HAE 133,024-258,025 (c)(72) 1,101 - 178,796 (73-74)
836 (2.8%) – 37,582 
(88%) (73-75)
1,042 - 745,376 (73,76-82) 33%-100% (73-76,78-82,85-89) <1% 1-64% (73-75,79-80,88-89)
JIA n/a 4,143 - 29,613 (93,95-96) 142 (6%) – 1,870 
(86%) (22,93-96,98)
2,202 - 27,603 (93,95-98) 7-54% (93-99) 3% (96) 22-40% (95-96,98)
MPS n/a n/a n/a 130,451 - 474,885 
(drug only) (28,101)
n/a n/a n/a
SCL n/a
12,032 - 14,133 (30,104-
105)
6,742 -11,357
(127% - 216%)
(30,103,105)
3,858 - 4,926 (30,105) 12-31%  (30-105) 0-4% (30-105) 28-82% (30,105)
PWS n/a n/a n/a n/a n/a n/a n/a
HIS n/a 49,947 (34)
14,842 
(64%) (34)
23,066 (34) 2% (34) 3% (d)(34) 1% (34)
EB n/a n/a n/a n/a n/a n/a n/a
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Source: The authors.
Notes: 1 CF=Cystic Fibrosis; DMD=Duchene Muscular Dystrophy; FXS=Fragile X Syndrome; HAE=Haemophilia; JIA=Juvenile 
Idiopathic Arthritis; MPS=Mucopolyssacharidosis; SCL=Scleroderma; PWS=Prader-Willi Syndrome; HIS=Hystiocytosis; 
EB=Epidermolysis bullosa.
(a) Depending on age, range limits are for 0-9 and 30-39 years(42)
(b) Patients with P. aeruginosa infection can incur >2-3x higher costs(15, 48)
(c) In the Mexican setting, using 5% discount rate
(d) One-time expense and therefore not included in annual direct cost. The 3.3% is total aids (€1,715) divided by total direct 
cost plus total aids (€49,947+€1,715).
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Figure 2. Availability of COI evidence versus disease prevalence
Source: The authors from the literature.
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